Clinical trials: Experimental
Healthy
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to…
- Trial name
- NCT03927209
- Testing
- BI 1467335
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Squamous Cell Carcinoma
Dose-Ranging Safety and Efficacy Study of Topical Creams Containing API 31510 for the Treatment of in Situ Cutaneous Squamous Cell Carcinoma
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound 31510 in a topical cream when applied to in situ cutaneous squamous cell carcinoma and to obtain preliminary efficacy data for the…
- Trial name
- NCT00605709
- Testing
- API 31510 Topical Cream
- Sponsor
- BPGbio
Type 2 Diabetes
A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01965509
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FG-3019, a therapeutic antibody designed to block the pro-fibrotic activity of connective tissue growth factor…
- Trial name
- NCT00074698
- Testing
- FG-3019
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kyntra Bio
Essential Hypertension
A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
This randomized, double-blind, multicenter phase 3 clinical trial evaluated the efficacy and safety of KDF1901, a single-pill triple combination of valsartan, amlodipine, and chlorthalidone, in patients with essential…
- Trial name
- NCT07116863
- Testing
- KDF1901-R0, KDF1901-L, KDF1901
- Where
- 2 sites in South Korea
- Volunteers
- 286 people
- Sponsor
- Kyungdong Pharmaceutical Co., Ltd.
Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy…
- Trial name
- NCT06829563
- Testing
- RZ-629, Fasted, Fed
- Where
- Australia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Rezubio Pharmaceuticals Co., Ltd.
Female Dry Genital Mucosa
Clinical Study for Perceived Effectiveness Evaluation of Moisturizing Action of Intimate Use Product in Postmenopausal Women
The purpose of this study is to verify the effectiveness of the investigational product through Subjective Assessment and answered by volunteers.
- Trial name
- CLIN ST EF EV (NCT02434887)
- Testing
- KL029 Intimate Lubricant Gel
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Kley Hertz S/A
Rubella, Varicella
Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' investigational measles, mumps, rubella and varicella (MMRV) vaccine (GSK208136, PriorixTetra™) when co-administered along with conjugated…
- Conditions
- Rubella, Varicella, Measles, Mumps
- Trial name
- NCT01506193
- Testing
- PriorixTetra™, Meningitec
- Where
- 13 sites in Italy
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Attention-Deficit / Hyperactivity Disorder
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
The main purpose of this study is to evaluate long-term safety and tolerability of JNS001 at 18 to 72 mg per day in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01357993
- Testing
- JNS001
- Where
- 29 sites in Japan
- Volunteers
- 253 people
- Sponsor
- Janssen Pharmaceutical K.K.
Ocular Hypertension, Primary Open Angle Glaucoma
A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.
- Trial name
- NCT01943721
- Testing
- VISION5 Product
- Where
- Latvia
- Volunteers
- 14 people
- Sponsor
- ForSight Vision5, Inc.
Dry Eye
Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness
This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of DM934 in comparison with Théalose in terms of cornea and conjunctiva staining (Oxford score)…
- Trial name
- NCT06245421
- Testing
- DM934, Théalose
- Where
- 5 sites in France, Poland and 2 more
- Volunteers
- 85 people
- Sponsor
- Horus Pharma
Thrombocytosis, Iron-Deficiency Anemia
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)
The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.
- Trial name
- NCT00882414
- Testing
- FERINJECT® (Ferric carboxymaltose)
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Vifor Pharma
Healthy Volunteer, Muscular Atrophy, Spinal
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
In this study, researchers will learn about a study drug called BIIB115 in healthy adult male volunteers and in participants with spinal muscular atrophy (SMA). This study will focus on children with SMA.
- Trial name
- NCT05575011
- Testing
- BIIB115
- Where
- 16 sites in Belgium, Canada and 7 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Biogen
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received…
- Trial name
- NCT02781571
- Testing
- SOF/VEL
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
Aphakia, Cataract
Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes
The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments…
- Trial name
- NCT03895034
- Testing
- Light Adjustable lens (LAL) and Light Delivery Device (LDD)
- Where
- Mexico
- Volunteers
- 66 people
- Sponsor
- RxSight, Inc.
Group A Streptococcal Infection
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of VAX-A1 in healthy adults 18-40 years of age.
- Trial name
- NCT07616934
- Testing
- VAX-A1 Low, VAX-A1 Mid, VAX-A1 High
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Coronary Artery Disease
VEST III PMS Clinical Protocol
Post marketing surveillance (PMS) study. 200 patients will be enrolled in a prospective, multi center, randomized, two-arm, open label, and controlled, enrolling patients with multi vessel atherosclerotic coronary artery disease…
- Trial name
- VEST III (NCT02511834)
- Testing
- VEST External Support, Coronary Artery Bypass Surgery
- Where
- 15 sites in Austria, Germany and 2 more
- Volunteers
- 184 people
- Sponsor
- Vascular Graft Solutions Ltd.
Non-cystic Fibrosis Bronchiectasis
A Clinical Study of RSS0343 in Healthy Subjects
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.
- Trial name
- NCT07289464
- Testing
- RSS0343 Tablets
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Reistone Biopharma Company Limited
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
- Conditions
- Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
- Trial name
- ART-AIN IIB-2 (NCT06206564)
- Testing
- Artesunate ointment
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Frantz Viral Therapeutics, LLC
Maxillary Sinusitis
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults
The objectives of the study were to confirm that a single, 2.0-g dose of azithromycin sustained release (SR) was at least as effective to 10 days of oral levofloxacin 500 mg once a day, when used to treat adults with…
- Trial name
- NCT00643409
- Testing
- azithromycin SR (Zithromax; compound: CP-62,993), levofloxacin
- Where
- 89 sites in United States, Argentina and 11 more
- Volunteers
- 541 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.